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Abstract Granulovacuolar degeneration (GVD) is char-
acterized by the presence of vacuolar cytoplasmic lesions in
nerve cells of the medial temporal lobe. These changes
occur in older non-diseased individuals as well as in
patients with Alzheimer’s disease (AD), progressive
supranuclear palsy (PSP), Pick’s, sporadic Parkinson’s
(PD), and Guam diseases. We stained representative par-
affin sections from all parts of the brain with anti-pTDP43,
anti-CK1d or anti-CK1e from 14 non-demented elderly, 19
AD, 17 non-AD tauopathy, 9 sporadic PD, and 5 TDP43-
proteinopathy [amyotrophic lateral sclerosis (ALS) and
frontotemporal lobar degeneration (FTLD)] cases. Our
results showed five stages of GVD based on its distribution
pattern: GVD began in the hippocampal subfields CA1,
CA2, and the subiculum. In a second stage, entorhinal
cortex, and CA4 neurons exhibited GVD. Additional neu-
rons were involved in the temporal neocortex in stage 3,
whereas the affection of the amygdala and/or the hypo-
thalamus marked stage 4. A fifth and final stage was
characterized by additional GVD in the cingulate cortex and
occasionally in the frontal and parietal cortices as well as in
the oral raphe and pedunculopontine tegmental nuclei. The
GVD stages correlated with neurofibrillary tangle stages,
Consortium to Establish a Registry for AD (CERAD) scores
for neuritic plaque pathology, amyloid b-protein deposition
phases, cerebral amyloid angiopathy stages, and clinical
dementia rating (CDR) scores. No associations were seen
between GVD stage and the presence of non-AD tauopa-
thies, PD, ALS, or FTLD cases. In conclusion, GVD affects
neurons in a hierarchical sequence that allows the distinc-
tion of five stages. The topographic distribution of GVD
restricted to regions involved in response to chronic stress
could indicate a link between GVD and chronically stressful
influences. Moreover, the association of the GVD stages
with those of AD-related pathology but not with other
neurodegenerative disorders points to a possible role of
GVD and the response to chronic stress in the pathogenesis
of AD.
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Introduction
Granulovacuolar degeneration (GVD) is marked by the
presence of vacuolar changes in the cytoplasm of neurons of
the medial temporal lobe (MTL) [4, 36, 49]. GVD lesions
have also been described in the neocortex, hypothalamus,
amygdala, and in the paramedian nuclei of the midbrain
[37]. GVD-affected neurons were more frequently seen in
Alzheimer’s disease (AD) cases than in controls [3, 14].
Other authors did not find such a correlation between GVD
and AD when comparing AD cases with non-demented
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cases with AD-related pathology [46]. Down syndrome
cases also exhibited GVD in age-related amounts rather
than in relation to AD-related neurofibrillary tangle (NFT)
pathology and synapse loss [5]. Moreover, GVD has been
reported in association with other tauopathies, such as
Guam disease [21], Pick’s disease, and progressive supra-
nuclear palsy (PSP) as well as in the synucleinopathies
sporadic Parkinson’s disease (PD) and dementia with Lewy
bodies [35]. Thus, although GVD is often referred to as an
‘‘AD-related’’ histopathological phenomenon it is, never-
theless, presently unclear whether it is only associated
with AD or with other tauopathies and with synucleinopa-
thies as well.
Recently, antibodies directed against the phosphorylated
transactive-response DNA-binding protein TDP43 (pTDP43)
and casein kinase 1 (CK1) isoforms d or e have been reported
to stain GVD [17, 25–27, 35]. They can be used to study GVD
pathology more easily than in hematoxylin–eosin or silver
stained sections.
To determine the anatomical distribution of GVD in the
human brain and to clarify its relationship to dementia
and AD, we studied non-demented elderly, AD, non-AD
tauopathy, sporadic PD, TDP43-proteinopathy cases for the
distribution of GVD and its relationship to concomitant
AD-related NFT and amyloid b-protein (Ab) pathology as
well as to sporadic PD, argyrophilic grain disease (AGD),
PSP, corticobasal degeneration (CBD), amyotrophic lateral
sclerosis (ALS), and frontotemporal lobar degeneration
(FTLD).
Materials and methods
Study cohort
A total sample of 64 autopsy cases between 59 and 98 years
of age covering all stages of AD-related NFT and Ab
pathology was investigated, including 14 non-demented
elderly, 19 AD, 17 non AD tauopathy (9 AGD, 8 PSP or
CBD), 9 PD, and 5 TDP43-proteinopathy (3 ALS and 2
FTLD) cases (Table 1). All autopsy brains were collected in
accordance with local ethical committee guidelines and the
federal law governing the use of human tissue in Germany
and The Netherlands. Scores from the clinical dementia
rating (CDR) [23] were observed retrospectively for 56
cases as previously described [42]. These data were also
employed to determine whether individuals clinically met
the DSM-IV criteria for dementia [2]. In three demented
cases, the clinical records noted the diagnosis of dementia
according to DSM-IV but did not provide sufficient infor-
mation to determine the CDR score. In five non-demented
cases, the clinical records did not provide sufficient infor-
mation to determine the CDR score.
AD was diagnosed when dementia was observed and
when the degree of AD-related neuropathology indicated at
least a moderate likelihood for AD according to acknowl-
edged criteria [45]. PD, PSP, CBD, ALS, and FTLD were
diagnosed neuropathologically in the event that clinical
recordings displayed respective deficits [1, 15, 18, 28, 39].
AGD was diagnosed when clinical records reported cog-
nitive deficits, the presence of argyrophilic grains could be
confirmed neuropathologically, and the amount of AD
related and vascular pathology alone failed to explain
dementia [24, 44].
Neuropathology and immunohistochemistry
The brains of all individuals were fixed in a 4% aqueous
formaldehyde solution for at least 3 weeks before undergoing
neuropathological evaluation. Tissue blocks covering the
regions listed in Table 2 were excised and embedded in
paraffin or polyethylene glycol (PEG; Merck-Schuchardt,
Hohenbrunn, Germany). The paraffin sections were cut
at 10 lm, whereas the PEG-blocks were sectioned at
100 lm.
For the detection of GVD and other neurodegenerative
lesions, silver staining methods and immunohistochemistry
with the primary antibodies listed in Table 3 were applied.
Primary antibodies were detected with biotinylated sec-
ondary antibodies and the ABC complex (Vectastain:
Vector Laboratories, Burlingame, CA, USA). This reaction
was subsequently visualized with 3,3-diaminobenzidine
(DAB). Immunolabeled paraffin sections were counter-
stained with hematoxylin. Positive and negative controls
were included to confirm immunostaining results. GVD
was diagnosed when multiple vacuoles (2 aggregated
vacuoles or more) with granular inclusions were detected
with at least one GVD-detecting antibody (Table 3). Soli-
tary autophagic vacuoles were not considered as GVD.
To confirm co-localization of CK1d, CK1e, and pTDP43
in GVD lesions, sections from the hippocampus of ran-
domly chosen cases exhibiting GVD were used for double
label immunofluorescence with anti-pTDP43 and either
anti-CK1d or anti-CK1e. The primary antibodies were
detected with carbocyanin Cy2 and Cy3 labeled secondary
antibodies. Sections were mounted in Eukitt (O. Kindler;
Freiburg, Germany) and cover-slipped. All tissue sections
were viewed with a Leica DMLB or an Olympus BX 51
microscope. Digital photographs were obtained with Leica
cameras (DC 500 or EC3).
Diagnosis of the stages in the development of NFTs
(NFT stage) and the semiquantitative assessment of neu-
ritic plaques [Consortium to Establish a Registry for AD
(CERAD) score] were performed in accordance with
published and recommended criteria [7, 9, 29, 45]. For
staging of Ab pathology, we used a previously published
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Table 1 List of autopsy cases studied
Case no. Age Sex Diagnosis CDR PD stage NFT stage Ab phase CERAD CAA stage GVD stage
1 66 f Control 0 n.a. 0 0 0 0 0
2 62 m Control 0 n.a. 0 0 0 0 0
3 64 m Control 0 n.a. 1 2 0 0 0
4 71 m Control 0 n.a. 1 3 0 0 0
5 61 m Control 0 n.a. 0 0 0 0 0
6 59 m Control 0 0 0 0 0 0 0
7 71 m Control 0 n.a. 1 2 0 1 1
8 69 f Control 0 n.a. 0 0 0 0 1
9 74 m Control 0 n.a. 1 0 0 0 2
10 83 f Control 0 n.a. 3 1 0 1 2
11 72 m Control 0 n.a. 3 2 0 0 3
12 83 f Control 0 n.a. 4 3 1 2 3
13 85 m Control 0 n.a. 3 2 1 0 4
14 63 f Control 0 n.a. 3 4 1 0 4
15 73 f AGD 0.5 n.a. 1 1 0 1 0
16 81 m AGD 2 n.a. 2 3 0 0 1
17 77 m AGD 0.5 n.a. 3 2 1 0 2
18 88 m AGD 2 n.a. 2 3 1 1 3
19 79 m AGD 2 n.a. 2 3 0 2 4
20 79 f AGD-VD 2 n.a. 2 0 0 0 4
21 80 f AGD, PD 1 3 2 3 0 0 0
22 79 m AGD, PD 0 3 2 0 0 0 1
23 75 m AGD, PSP, PD 2 4 3 2 0 1 0
24 78 f CBD 3 n.a. 1 1 0 0 1
25a 76 m PSP 0 n.a. 0 2 0 0 0
26a 69 f PSP 0 n.a. 2 1 0 0 0
27b 59 m PSP n.a. n.a. 2 1 0 1 0
28a 81 m PSP 2 n.a. 4 4 2 3 2
29a 76 m PSP 1 n.a. 1 1 0 0 3
30b 83 m PSP n.a. n.a. 3 2 0 0 4
31a 84 f PSP, AGD 0 n.a. 0 0 0 1 0
32 83 f PD n.a. 4 2 0 0 0 0
33 69 f PD n.a. 4 1 3 0 1 0
34 68 f PD 2 5 1 3 0 1 0
35 77 m PD 0 4 1 0 0 0 0
36b 76 m PD n.a. 5 3 4 0 1 0
37 64 f PD 0 4 3 0 0 1 1
38 68 m PD 0.5 5 3 4 2 2 1
39 76 f PD 0 4 2 0 0 0 1
40 77 m PD 1 5 4 3 2 2 1
41 68 m ALS 0 n.a. 2 2 0 1 2
42 75 m ALS 0 n.a. 2 1 1 1 2
43 76 f ALS 0 n.a. 2 0 0 0 2
44c 76 f FTLD-TDP 3 n.a. 0 3 0 2 0
45 84 m FTLD-TDP, AD, DLB 3 6 6 4 3 2 5
46 64 f AD n.a. n.a. 6 4 3 1 1
47 62 f AD 3 n.a. 6 4 3 1 2
48 72 f AD 1 n.a. 4 4 2 1 2
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protocol for four phases of b-amyloidosis in the MTL [43].
Cerebral amyloid angiopathy (CAA) was diagnosed when-
ever vascular Ab deposition was observed. The stage of the
distribution of CAA-affected vessels throughout the brain was
assessed according to published criteria [40, 41]. PD lesions
in PD cases were staged according to previously published
criteria [1, 11].
Statistical analysis
The presence or absence of GVD in a given brain region
was assessed dichotomously with anti-pTDP43, anti-CK1d,
and/or anti-CK1e. The brain areas listed in Table 2 were
analyzed separately. Cluster analysis was performed to
identify a staging pattern. The staging pattern was validated
by testing the stage-related affection with GVD for each
region studied with the Fisher’s exact-test and subsequent
trend-test. Partial correlation analysis controlled for age and
gender was performed to describe the relationship between
GVD stage and AD-related pathology as well as between
GVD stage and the CDR score. Logistic regression analysis
was performed controlling for age and gender to test whe-
ther AD was associated with the stages of GVD pathology.
Likewise, logistic regression was used to analyze the
association between non-AD tauopathies (i.e., AGD, PSP,
and CBD), PD, and TDP43-proteinopathies (ALS, FTLD)
on the one hand and the GVD stages on the other. All sta-
tistical tests were calculated with the help of SPSS-
statistical software, release 19.0 (Chicago, IL, USA). To
correct for multiple testing Bonferroni correction was used.
Results
Anti-pTDP43 stained GVD similar to anti-CK1d and anti-
CK1e (Fig. 1a–c). Positively stained material lacking the
typical vacuolar pattern was not considered as GVD.
Double label immunofluorescence confirmed the presence
of CK1d and CK1e, both antibodies co-localizing pTDP43
in GVD lesions (Fig. 1d–i). With these antibodies, a sim-
ilar distribution pattern throughout all investigated brain
regions was observed, thereby indicating that these meth-
ods were interchangeable for GVD staging. A region-
specific differential expression of these proteins in GVD
lesions was not seen. Immunohistochemistry with the
antibody against abnormal s protein appeared less useful
Table 1 continued
Case no. Age Sex Diagnosis CDR PD stage NFT stage Ab phase CERAD CAA stage GVD stage
49 86 f AD 3 n.a. 6 4 2 2 3
50 87 f AD 3 n.a. 4 4 1 2 3
51 87 f AD 0.5 n.a. 4 4 2 2 3
52 79 f AD n.a. n.a. 4 3 2 1 4
53 82 m AD 2 n.a. 3 3 2 1 4
54 89 f AD 3 n.a. 5 4 3 2 4
55 98 f AD 2 n.a. 4 4 3 2 4
56 68 f AD 1 n.a. 6 4 2 1 4
57 78 m AD 3 n.a. 4 4 1 2 4
58 83 f AD n.a. n.a. 4 4 2 1 5
59 78 m AD 1 n.a. 4 4 1 1 5
60 81 f AD 3 n.a. 5 4 1 1 5
61 83 m AD 3 n.a. 5 4 2 3 5
62 83 m AD 3 n.a. 4 4 3 2 5
63 98 f AD 0.5 n.a. 4 4 1 2 5
64 78 f AD 3 n.a. 5 4 2 3 5
The table shows age in years, sex, neuropathological diagnosis, the degree of dementia (CDR score) [31], the PD stage according to Braak et al.
[11], the stage of neurofibrillary tangle pathology according to Braak and Braak [9] (NFT stage), the Ab phase representing the distribution of Ab
deposits in the subfields of the MTL [43], the CERAD score for the frequency of neuritic plaques according to Mirra et al. [29], the stages of
CAA [40], and GVD
m Male, f female, (control) non-demented control, AD Alzheimer’s disease, AGD argyrophilic grain disease, ALS amyotrophic lateral sclerosis,
CBD corticobasal degeneration, DLB dementia with Lewy bodies, FTLD-TDP frontotemporolobar degeneration with TDP43-pathology, n.a. not
assessed, PD Parkinson’s disease, PSP progressive supranuclear palsy, VD vascular dementia
a Indicates cases for which brain stem and diencephalic samples were not available
b Indicates cases for which samples of the occipital lobe were not available
c Indicates cases for which samples of diencephalic regions and the parietal cortex were not available
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for GVD detection because this antibody also stained other
s lesions [16]. Therefore, the identification of GVD lesions
was more difficult than with the other three antibodies.
The distribution of typical pTDP43- and CK1d/e-posi-
tive GVD throughout the brain regions investigated
revealed a five-staged hierarchical pattern (Figs. 2, 3, 4, 5,
6; Table 2). The CA1/2-subiculum region always exhibited
GVD whenever GVD was observed, regardless whether
other brain regions were involved as well. Thus, GVD in the
CA1/2 subiculum region in the absence of GVD elsewhere
Table 2 Frequencies of GVD prevalence in the brain regions studied at each stage of GVD
GVD Stage 1 GVD Stage 2 GVD Stage 3 GVD Stage 4 GVD Stage 5
CA1/subiculum* 100.00% 100.00% 100.00% 100.00% 100.00%
entorhinal cortex (Brodmann area 28)* 0.00% 75.00% 100.00% 100.00% 100.00%
CA4* 0.00% 50.00% 80.00% 77.78% 100.00%
temporal cortex (Brodmann area 35/36)* 0.00% 0.00% 100.00% 100.00% 100.00%
NBM* 0.00% 0.00% 20.00% 55.56% 50.00%
Hypothalamus* 0.00% 0.00% 0.00% 88.89% 100.00%
Amygdala* 0.00% 0.00% 0.00% 77.78% 100.00%
cingulate gyrus (Brodmann area 24)* 0.00% 0.00% 0.00% 0.00% 75.00%
Oral raphe/ PPTg nuclei* 0.00% 0.00% 0.00% 0.00% 62.50%
Thalamus 0.00% 0.00% 0.00% 0.00% 37.50%
frontal cortex (Brodmann area 6) 0.00% 0.00% 0.00% 0.00% 12.50%
parietal cortex (Brodmann area 7) 0.00% 0.00% 0.00% 0.00% 12.50%
occipital cortex (Brodmann areas 17, 18, 19) 0.00% 0.00% 0.00% 0.00% 0.00%
basal ganglia 0.00% 0.00% 0.00% 0.00% 0.00%
cerebellum 0.00% 0.00% 0.00% 0.00% 0.00%
substantia nigra 0.00% 0.00% 0.00% 0.00% 0.00%
red nucleus 0.00% 0.00% 0.00% 0.00% 0.00%
brain stem motor neurons 0.00% 0.00% 0.00% 0.00% 0.00%
brain stem sensory neurons 0.00% 0.00% 0.00% 0.00% 0.00%
brain stem visceromotoric and -sensoric nuclei 0.00% 0.00% 0.00% 0.00% 0.00%
inferior olivary nucleus 0.00% 0.00% 0.00% 0.00% 0.00%
pontine nuclei 0.00% 0.00% 0.00% 0.00% 0.00%
It is shown which percent of cases in a given GVD stage exhibit GVD lesions in a given region. For visualization the frequencies are color-coded:
0% of the cases exhibit GVD lesions = white; 1–25% of the cases exhibit GVD lesions = 20% gray; 26–50 % of the cases exhibit GVD
lesions = 40 % gray; 51–75% of the cases exhibit GVD lesions = 60% gray; 76–99% of the cases exhibit GVD lesions = 80% gray; all cases
exhibit GVD lesions = black
* indicates those regions that significantly showed differences in the distribution of GVD among the GVD stages (Fisher’s exact-test:
* p \ 0.005) with a trend to increase with advancing GVD stage (trend-test: * p \ 0.005)
Table 3 List of the conventional and immunohistochemical staining techniques used for the detection of neurodegenerative changes in this
study
GVD NFT/
NT
Senile
plaques
Lewy
bodies
Glial s
inclusions
TDP43 threads/
NCI/Nucl.
inclusions
Reference/clone, distributor, dilution, pretreatment
Gallyas ? ? [8]
Campbell-Switzer ? ? [8, 34]
Anti-abnormal
s protein
? ? ? AT-8, Pierce-Endogen, USA, 1/1,000
Anti-amyloid b
protein
? 4G8, Covance, Dedham, USA, 1/5,000,
formic acid pretreatment
Anti-a synuclein ? anti-syn-1; 1:2,000; Clone number 42,
BD Biosciences, Mountain View, CA, USA
Anti-pTDP43 ? ? pS409/410-2, Cosmo Bio Co., Ltd, Tokyo, Japan,
1/10,000, microwave pretreatment
Anti-CK1d ? 108, l polyclonal rabbit, [38], 1/200, microwave
pretreatment
Anti-CK1e ? 712 polyclonal rabbit [13], 1/600, microwave pretreatment
H-60 polycloncal rabbit, Santa Cruz Biotechnology; Santa
Cruz, CA, USA, 1/150, microwave pretreatment
The table indicates which lesions are detected with a given method. The detection of GVD with anti-abnormal phosphorylated s antibodies is
possible [16] but is less easy to analyze because other tauopathic lesions are stained as well as with this antibody
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in the brain was referred to as stage 1 GVD (Fig. 2). In
addition to GVD in the CA1/2 subiculum region, this
pathology was also observed in the entorhinal cortex
(Brodmann area 28) in neurons of layers pre-a, pre-b, pri-a,
and pri-b and/or in the CA4 subfield of the Ammon’s horn
(Table 2). GVD in CA4 can be accompanied by GVD
lesions in CA3. Stage 2 GVD cases are characterized by this
pathology in the absence of further GVD pathology except
for occasional GVD-affected neurons in the basal nucleus
of Meynert (Fig. 3; Table 2). Expansion of this pathology
into layers II/III and/or V of the temporal neocortex
(Brodmann areas 35 and 36) (Table 2) was referred to as
GVD stage 3 (Fig. 4). In GVD stage 4, GVD-containing
neurons were also observed in the amygdala (amygdalo-
hippocampal area, amygdalo-piriform area, central amyg-
daloid nucleus, basolateral and basomedial nuclear
complexes) and/or in hypothalamic neurons of the
tuberomammillary, paraventricular, supraoptic, ventrome-
dial, dorsomedian, medial mammillary nuclei and/or nuclei
of the anterior and lateral hypothalamic area (Fig. 5;
Table 2). In the final stage, GVD stage 5, GVD was
observed in layers II/III and V neurons of the cingulate
gyrus (area 24) as well as in the oral raphe nuclei, the pe-
dunculopontine tegmental nucleus, the superficial and
medial thalamic nuclei. Occasionally, GVD lesions were
also found in the frontal (Brodmann area 6) and parietal
neocortex (Brodmann area 7) (Fig. 6; Table 2). As indi-
cated in Table 2, the presence or absence of GVD in given
brain regions resulted in significant differences among the
GVD stages. The trend-test confirmed the hierarchical
involvement of more and more brain regions (Table 2).
With advancing GVD stage, an increase was also noted
in the NFT stage, the CERAD score for neuritic plaques,
the phase of Ab deposition in the MTL, the CAA stage, and
Fig. 1 a–c GVD lesions in the
subiculum-CA1 region were
detected with anti-pTDP43
(arrow in a), with anti-CK1d
(arrow in b), and with anti-
CK1e (arrow in c). Double label
immunofluorescence analyses
revealed co-expression of
pTDP43 and CK1d (d–f arrows)
and of pTDP43 and CK1e
(g–i arrows). (a, c case no. 20;
b case no. 25; d–f case no. 29;
g–i case no. 26). Calibration
bar in c is valid for: a–c 8 lm;
d–i 13 lm
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the degree of dementia as represented by the CDR score
(Fig. 7a). GVD stage correlated with the NFT stage (partial
correlation coefficient for age and gender: r = 0.624, p \
0.002), with the CERAD neuritic plaque score (partial cor-
relation coefficient for age and gender: r = 0.526, p \
0.002), the Ab phase for plaque deposition in the MTL
(partial correlation coefficient for age and gender: r =
0.454, p \ 0.002), CAA stage (partial correlation coeffi-
cient for age and gender: r = 0.298, p = 0.038), and the
CDR score for dementia (Partial correlation coefficient for
age and gender: r = 0.347, p = 0.020) (Fig. 7a). After
exclusion of the AD cases, there was still a correlation with
NFT stage (partial correlation coefficient for age and gen-
der: r = 0.462, p = 0.006) in the group of all non-AD cases
whereas no significant correlation was observed for CERAD
neuritic plaque score (p = 0.053), Ab phase (p = 0.711),
CAA stage (p = 0.999), and CDR score (p = 0.946).
Finally, logistic regression analysis controlled for age
and gender revealed an association of AD with the GVD
stage (Fig. 7b; odds ratio = 2.741, 95% CI: 1.59–4.724,
p \ 0.004). After exclusion of the AD cases, non-AD
tauopathies (AGD, PSP and CBD), sporadic PD and
TDP43-proteinopathies (ALS/FTLD) were not associated
with the GVD stage in our sample (Fig. 7c; non-AD
Fig. 2 GVD stage 1: GVD-
affected neurons (marked in
red) were limited to the CA1-
subiculum regions (arrows).
The right diagram depicts the
forebrain hemisphere at the
level of the entorhinal region
and the hypothalamus, the left
shows a section at the level of
the lateral geniculate body and
the substantia nigra. Anatomical
orientation: Amy amygdala, Bgl
basal ganglia, incl. Caudate
nucleus, putamen and globus
pallidus, CA1 CA1/subiculum
sector of the hippocampus, CA4
CA4 sector of the hippocampus,
cing cingulate gyrus, ER
entorhinal cortex, F frontal
cortex, Hypoth hypothalamus,
MB midbrain, NBM basal
nucleus of Meynert, T temporal
cortex, Thal thalamus
Fig. 3 GVD stage 2: In
addition to neurons affected in
GVD stage 1 entorhinal and
CA4 neurons exhibited GVD as
well (arrows). GVD-affected
neurons are marked in red.
Basal nucleus of Meynert
neurons only occasionally
exhibited GVD-affected
neurons and were, therefore, not
included in this schematic
representation because this
region was not relevant for
staging
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tauopathies: p = 0.473; PD: p = 0.186; TDP43-protein-
opathies: p = 0.989).
Discussion
Here, we show that GVD represents a pathological lesion
in the brain that first develops in neurons of the CA1/2-
subiculum region and, thereafter, expands in a predictable
sequence into neurons of additional brain regions. This
hierarchical distribution pattern makes it possible to dis-
tinguish five GVD stages (Figs. 2, 3, 4, 5, 6):
Stage 1 GVD occurs only in the CA1/2-subiculum
region.
Stage 2 GVD is found in the CA1/2-subiculum region,
and additionally in the entorhinal cortex and/or
CA4; CA3, and the basal nucleus of Meynert can
occasionally exhibit GVD-affected neurons in
this stage.
Stage 3 Stage 2 regions and the temporal neocortex
display the presence of GVD.
Stage 4 GVD is localized in stage 3 regions, subnuclei of
the amygdala, and/or the hypothalamus.
Fig. 4 GVD stage 3: Further
GVD-affected neurons (marked
in red) in addition to those
already showing GVD in stage 2
were found in the temporal
neocortex (area 36) (arrows).
Basal nucleus of Meynert
neurons only occasionally
exhibited GVD-affected
neurons and were, therefore, not
included in this schematic
representation because this
region was not relevant for
staging
Fig. 5 GVD stage 4: GVD-
affected neurons (marked in
red) were found in the amygdala
and in the hypothalamus
(arrows) in addition to those in
areas already affected in stage 3.
Basal nucleus of Meynert
neurons only occasionally
exhibited GVD-affected
neurons and were, therefore, not
included in this schematic
representation because this
region was not relevant for
staging
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Stage 5 GVD is seen in the CA1/2-subiculum region,
entorhinal cortex, CA4, temporal neocortex,
subnuclei of the amygdala and the hypothalamus,
oral raphe nuclei, pedunculopontine tegmental
nucleus, cingulate gyrus, and occasionally in the
superficial and medial nuclei of the thalamus,
frontal and parietal neocortex.
This staging system confirms the findings of earlier
studies that the CA1/2-subiculum region is a predilection
site for GVD [4, 49] and, as reported by other groups [4, 37,
49, 50], that GVD, when present, occurs in the hippocampus,
entorhinal, temporal and cingulate gyrus, hypothalamus,
and amygdala. However, we also found GVD at additional
sites, including the oral raphe nuclei, the pedunculopontine
tegmental nucleus, superficial and medial thalamic nuclei,
the basal nucleus of Meynert, and occasionally in other
neocortical areas, whereby the visual cortex (Brodmann
areas 17–19) appeared to be spared. The overall distribu-
tion pattern of GVD in our study corresponds to that
described by other authors [50] and, as shown here, it also
correlates with the distribution pattern of AD-related NFTs
(NFT stage), Ab plaques (Ab phase), neuritic plaques
(CERAD neuritic plaque score), CAA (CAA stage), and
with the degree of dementia (CDR score). This correlation
was not explained by age and gender effects since partial
correlation analysis was appropriately controlled for age
and gender. As such, it appears more than likely that GVD
represents a fourth pathological hallmark of AD in addition
to NFTs, Ab plaques and CAA.
Other neurodegenerative diseases such as PD, non-AD
tauopathies (including AGD, PSP, CBD), and TPD43-
proteinopathies, such as ALS/FTLD were not associated
with increased GVD stages although GVD (mean GVD
stage 1.29; range 0–5) was observed in 42–80% of these
cases similar to age-matched controls. Logistic regression
models controlled for age and gender confirmed the asso-
ciation of GVD stage with AD. Therefore, the expansion of
GVD pathology in its end stage distribution pattern appears
to be AD related. An argument against this hypothesis is
that GVD also occurs in up to 80% of cases with PSP,
AGD, PD, ALS, and FTLD-TDP43. The extent, however,
of the GVD lesions throughout the brain most frequently
corresponded to early GVD stages, which could just as
easily be explained by the presence of concomitant AD-
related pathology in these cases. Since nearly all individ-
uals who died at the age of 40 years or older have been
shown to exhibit at least minimal AD-like s pathology in
the brain stem [12] we were unable to find a single ‘‘pure’’
GVD case in the absence of early s lesions. These latest
results may provide additional evidence in favor of a link
between GVD and AD. Another argument against GVD as
an AD-related pathology is that vacuolar lesions in bal-
looned neurons have been described previously as GVD in
a familial PD case [30]. Nonetheless, this study did not take
into account that CK1d and CK1e failed to stain GVD
within ballooned neurons in our CBD and AGD cases as
well as in the sample reported by Schwab et al. [35].
Because we did not study Pick disease cases we cannot
exclude an association of this disorder with the extent of
GVD-affected neurons as represented by the GVD stage
similar to that seen in AD cases.
When comparing studies about GVD it seems to be of
major importance to compare the determination of GVD
Fig. 6 GVD stage 5: The final
stage of GVD distribution
showed GVD-affected neurons
(marked in red) in the cingulate
gyrus, other neocortical regions,
the thalamus and the raphe
nuclei and/or the
pedunculopontine tegmental
nucleus (PPTg; arrows).
Neurons of the basal nucleus of
Meynert were also affected
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used by the authors. Here, we determined GVD as pTDP43-,
CK1d- and CK1e-positive accumulations of at least two
aggregated vacuoles containing granular inclusions. We
considered solitary vacuoles as autophagic vacuoles but not
as GVD even when they were stained.
The stages of GVD proposed here describe the biolog-
ical process of a hierarchical expansion of this pathology
throughout the brain. As such, the GVD stages describe a
parameter that is related to the severity of GVD and
independently of neuronal loss, which decreases, e.g., the
number of CA1 neurons exhibiting GVD, in end-stage AD
cases. Since Ab and s targeting treatment strategies against
AD have been unsuccessful to date [22, 32, 48] GVD
presumably will be important for the understanding of AD-
related pathomechanisms as well as for the identification of
alternative therapeutic targets. In contrast to this potential
scientific relevance of GVD and GVD stages, GVD does
not contribute to the clinical and neuropathological diag-
nosis of AD in addition to s and Ab pathology. Therefore,
although we do not recommend staging or even diagnosis
of GVD lesions for routine neuropathological use, we do
recommend it as a parameter for neuropathological studies
of neurodegenerative disorders as well as for brain banking
purposes. Especially when studying NFT pathology, e.g.,
within the context of AD, biochemical analysis cannot
distinguish between s protein derived from NFTs and s
protein derived from GVD. Therefore, it is necessary to
focus on regions with NFT-only pathology, i.e. regions that
do not exhibit GVD when analyzing NFT-related s
pathology.
GVD is not directly linked to NFT pathology or Ab
plaque deposition. Two 62-year-old AD cases from our
sample with NFT stage VI, Ab-phase 4 but only GVD
stages 1 and 2, respectively, support this hypothesis. A
non-demented control case (No. 14) exhibiting GVD stage
4, NFT stage III, and Ab phase 4 demonstrates, on the other
hand, that GVD, NFT, and Ab pathology alone do not
explain dementia, as seen in AD case No. 53 with GVD
stage 4, NFT stage III, and Ab phase 3. Here, the presence
or absence of CAA might explain dementia. Thus, GVD
itself accounts for the development of late–onset AD,
although other factors, such as age of onset, genetic
background, NFTs, and parenchymal and vascular Ab
pathology, significantly contribute as well. It needs to be
clarified in the future whether GVD distinguishes specific
types of AD or represents a late–onset AD phenomenon.
An argument favoring the latter hypothesis is the finding of
Ball et al. [5] that GVD does not play a role in Down
syndrome cases even when they show severe neurofibril-
lary pathology.
Neurons exhibiting GVD lesions in our study occurred
in regions involved in response to chronic stress [47] and in
the modulation of the sleep-wakefulness state [33]. GVD
involved neurons of the top–down regulation circuit of the
autonomic response to chronic stress, i.e., the hippocampus
(CA1, CA2, CA4, subiculum), entorhinal cortex with
Fig. 7 a Relationship between GVD stage and neurofibrillary
pathology (NFT stage), neuritic plaque pathology (CERAD score),
Ab pathology (Ab phase), CAA (CAA stage), and the degree of
dementia as represented by the CDR score. The increase of the GVD
stage correlated with that of NFT stage, CERAD score, Ab phase,
CAA stage, and the degree of dementia as represented by the CDR
score (partial correlation analysis controlled for ages and sex:
r = 0.33–0.624; p \ 0.05). b AD cases exhibited higher GVD stages
than non-AD controls (*p \ 0.004). c After exclusion of the AD cases
non-AD tauopathy cases (covering AGD, PSP, and CBD), PD cases
and TDP43-proteinopathy cases (covering ALS and FTLD-TDP) did
not exhibit higher GVD stages than controls
586 Acta Neuropathol (2011) 122:577–589
123
adjacent temporal cortex, cingulate gyrus, prefrontal cor-
tex, amygdala, and hypothalamus. Each of these regions
receives input from the locus coeruleus which is a major
wakefulness-promoting nucleus [6, 33] that becomes acti-
vated in response to chronic stressors [47]. A central role
for the locus coeruleus in the pathogenesis of AD has been
discussed recently because this nucleus exhibits s pathol-
ogy very early in life [10, 12] and its degeneration has been
shown to promote the development of AD-related lesions
in experimental animal models of AD [19, 20]. Thus, one
may speculate that chronically stressful influences and
disturbed sleep-wakefulness modulation may play a role in
the pathogenesis of AD. GVD appears to represent a
morphological correlative for the alteration of nerve cells
owing to chronic stress response. Further studies are
required to verify this hypothesis. Single cell analysis of
GVD-affected neurons as well as detection of chronic
stress-induced inflammatory response may help to clarify
this issue.
In summary, we show here that GVD lesions extend into
increasing numbers of brain regions in an ordered sequence
that allows the distinction of five stages. In this process, the
expansion of GVD lesions correlates with the distribution
of AD-related neuropathological lesions but not with other
tauopathies (PSP, AGD, CBD), sporadic PD, and TDP43-
proteinopathies (ALS/FTLD-TDP)—an indication that
GVD is associated with AD but not with neurodegeneration
in general. In addition, the anatomical distribution pattern
of GVD in the brain corresponds to regions involved in
chronic stress response and in sleep-wakefulness modula-
tion. Taken together, these points permit us to hypothesize
that GVD anatomically related to chronic stress and its
processing by the brain may contribute to the development
of AD as a fourth factor in addition to the intraneuronal
aggregation of s protein, Ab deposition in senile plaques,
and CAA.
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